The DNA repair drugs market size has grown exponentially in recent years. It will grow from $10.78 billion in 2024 to $13.11 billion in 2025 at a compound annual growth rate (CAGR) of 21.6%. The growth in the historic period can be attributed to increasing understanding of DNA repair mechanisms, growth in cancer research, evolving regulatory landscape for pharmaceuticals, rising prevalence of genetic disorders, expansion of personalized medicine.
The DNA repair drugs market size is expected to see exponential growth in the next few years. It will grow to $27.22 billion in 2029 at a compound annual growth rate (CAGR) of 20%. The growth in the forecast period can be attributed to development of targeted therapies for DNA repair, growing focus on precision medicine, rise in the aging population, increased funding for DNA repair drug development. Major trends in the forecast period include integration of artificial intelligence in drug discovery for DNA repair, development of combination therapies targeting DNA repair pathways, emphasis on gene editing technologies, personalized treatment regimens based on DNA repair profiles, rise in clinical trials for DNA repair drugs.
The increasing prevalence of cancer is anticipated to drive the growth of the DNA repair drug market in the future. Cancer can develop in almost any organ or tissue when abnormal cells grow uncontrollably, exceeding their typical boundaries and potentially spreading to other organs or invading nearby tissues. This rise in cancer cases is primarily attributed to factors such as smoking, radiation exposure, carcinogenic substances, obesity, and genetic mutations. By hindering DNA's self-repair capabilities, these drugs can cause cancerous cells to cease replication and eventually die. For example, the Australian Institute of Health and Welfare reported that the number of cancer diagnoses in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a significant annual increase. This trend underscores the growing prevalence of cancer in the country, which in turn is fueling the expansion of the DNA repair drug market.
The growing demand for personalized medicine is expected to drive the expansion of the DNA repair drug market in the future. Personalized medicine is an innovative approach to healthcare that considers individual differences in patients’ genes, environments, and lifestyles. DNA repair drugs are vital in this field, as they allow treatments to be tailored to the unique genetic profiles of patients. These drugs are used in personalized medicine for cancer treatment, biomarker identification, and minimizing adverse effects, among other applications. For example, the Personalized Medicine Coalition reported that in 2022, the approval of 12 new personalized medicines accounted for about 34% of all newly approved therapies, marking a significant increase compared to previous years. Thus, the rising demand for personalized medicine is fueling the growth of the DNA repair drug market moving forward.
DNA repair drug market is witnessing a prominent trend of product innovation. Leading companies in the DNA repair drugs sector are actively engaged in developing groundbreaking products to fortify their market presence. A notable example is AstraZeneca PLC, a UK-based biopharmaceutical company, which secured approval in June 2023 for Lynparza plus abiraterone in the United States. This approval is specifically for treating BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib), the first-of-its-kind PARP inhibitor, represents a breakthrough as the initial targeted drug capable of blocking the DNA damage response (DDR) in cells or tumors without homologous recombination repair (HRR).
Major players in the DNA repair drug market are directing their efforts toward the development of innovative solutions, such as oral poly ADP-ribose polymerase (PARP) inhibitors. These medications, administered orally, are designed to target the PARP enzyme's activity. Pfizer Inc., a prominent US-based pharmaceutical company, exemplifies this trend with the FDA approval announcement in June 2023 for 'TALZENNA' (talazoparib). TALZENNA, the first and only PARP inhibitor approved for use alongside the established standard of care, XTANDI, is intended for adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) exhibiting mutations in homologous recombination repair (HRR) genes. By inhibiting PARP enzyme activity and capturing PARP at the DNA damage site, TALZENNA hinders cancer cell growth and induces cell death.
In November 2022, Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company specializing in rare disorder therapies, acquired LogicBio Therapeutics Inc. for an undisclosed sum. This acquisition positions Alexion to expedite its foray into genomic therapeutics, leveraging LogicBio's distinctive technology, seasoned rare disease R&D team, and expertise in pre-clinical development. LogicBio Therapeutics Inc. is a clinical-stage genetic medicine company with a focus on gene delivery and gene editing platforms to address rare diseases.
Major companies operating in the DNA repair drugs market include Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Biogen Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., BioMarin Pharmaceutical Inc., Genentech Inc., ClovisOncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., Intellia Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA, CRISPR Therapeutics AG.
North America was the largest region in the DNA repair drugs market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the dna repair drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna repair drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
DNA repair drugs are therapeutic agents aimed at enhancing or restoring the body's natural mechanisms for repairing damaged DNA in cells. These medications are utilized to treat a variety of conditions, including cancer, by encouraging the repair of genetic mutations and boosting the efficacy of other treatments such as chemotherapy and radiation.
The primary types of DNA repair drugs include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib, for instance, is a medication prescribed for adults dealing with specific forms of prostate cancer, pancreatic cancer, breast cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, either as a standalone treatment or in combination with other medications. These drugs are made available through hospital pharmacies, retail pharmacies, and other distribution channels for the treatment of conditions such as ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and more.
The DNA repair drugs research report is one of a series of new reports that provides DNA repair drugs market statistics, including the DNA repair drugs industry's global market size, regional shares, competitors with DNA repair drugs market share, detailed DNA repair drugs market segments, market trends and opportunities, and any further data you may need to thrive in the DNA repair drugs industry. This DNA repair drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The DNA repair drugs market consists of sales of veliparib, methyl methane sulfonate, mitomycin C, and cisplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The DNA repair drugs market size is expected to see exponential growth in the next few years. It will grow to $27.22 billion in 2029 at a compound annual growth rate (CAGR) of 20%. The growth in the forecast period can be attributed to development of targeted therapies for DNA repair, growing focus on precision medicine, rise in the aging population, increased funding for DNA repair drug development. Major trends in the forecast period include integration of artificial intelligence in drug discovery for DNA repair, development of combination therapies targeting DNA repair pathways, emphasis on gene editing technologies, personalized treatment regimens based on DNA repair profiles, rise in clinical trials for DNA repair drugs.
The increasing prevalence of cancer is anticipated to drive the growth of the DNA repair drug market in the future. Cancer can develop in almost any organ or tissue when abnormal cells grow uncontrollably, exceeding their typical boundaries and potentially spreading to other organs or invading nearby tissues. This rise in cancer cases is primarily attributed to factors such as smoking, radiation exposure, carcinogenic substances, obesity, and genetic mutations. By hindering DNA's self-repair capabilities, these drugs can cause cancerous cells to cease replication and eventually die. For example, the Australian Institute of Health and Welfare reported that the number of cancer diagnoses in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a significant annual increase. This trend underscores the growing prevalence of cancer in the country, which in turn is fueling the expansion of the DNA repair drug market.
The growing demand for personalized medicine is expected to drive the expansion of the DNA repair drug market in the future. Personalized medicine is an innovative approach to healthcare that considers individual differences in patients’ genes, environments, and lifestyles. DNA repair drugs are vital in this field, as they allow treatments to be tailored to the unique genetic profiles of patients. These drugs are used in personalized medicine for cancer treatment, biomarker identification, and minimizing adverse effects, among other applications. For example, the Personalized Medicine Coalition reported that in 2022, the approval of 12 new personalized medicines accounted for about 34% of all newly approved therapies, marking a significant increase compared to previous years. Thus, the rising demand for personalized medicine is fueling the growth of the DNA repair drug market moving forward.
DNA repair drug market is witnessing a prominent trend of product innovation. Leading companies in the DNA repair drugs sector are actively engaged in developing groundbreaking products to fortify their market presence. A notable example is AstraZeneca PLC, a UK-based biopharmaceutical company, which secured approval in June 2023 for Lynparza plus abiraterone in the United States. This approval is specifically for treating BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib), the first-of-its-kind PARP inhibitor, represents a breakthrough as the initial targeted drug capable of blocking the DNA damage response (DDR) in cells or tumors without homologous recombination repair (HRR).
Major players in the DNA repair drug market are directing their efforts toward the development of innovative solutions, such as oral poly ADP-ribose polymerase (PARP) inhibitors. These medications, administered orally, are designed to target the PARP enzyme's activity. Pfizer Inc., a prominent US-based pharmaceutical company, exemplifies this trend with the FDA approval announcement in June 2023 for 'TALZENNA' (talazoparib). TALZENNA, the first and only PARP inhibitor approved for use alongside the established standard of care, XTANDI, is intended for adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) exhibiting mutations in homologous recombination repair (HRR) genes. By inhibiting PARP enzyme activity and capturing PARP at the DNA damage site, TALZENNA hinders cancer cell growth and induces cell death.
In November 2022, Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company specializing in rare disorder therapies, acquired LogicBio Therapeutics Inc. for an undisclosed sum. This acquisition positions Alexion to expedite its foray into genomic therapeutics, leveraging LogicBio's distinctive technology, seasoned rare disease R&D team, and expertise in pre-clinical development. LogicBio Therapeutics Inc. is a clinical-stage genetic medicine company with a focus on gene delivery and gene editing platforms to address rare diseases.
Major companies operating in the DNA repair drugs market include Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Biogen Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., BioMarin Pharmaceutical Inc., Genentech Inc., ClovisOncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., Intellia Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA, CRISPR Therapeutics AG.
North America was the largest region in the DNA repair drugs market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the dna repair drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna repair drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
DNA repair drugs are therapeutic agents aimed at enhancing or restoring the body's natural mechanisms for repairing damaged DNA in cells. These medications are utilized to treat a variety of conditions, including cancer, by encouraging the repair of genetic mutations and boosting the efficacy of other treatments such as chemotherapy and radiation.
The primary types of DNA repair drugs include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib, for instance, is a medication prescribed for adults dealing with specific forms of prostate cancer, pancreatic cancer, breast cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, either as a standalone treatment or in combination with other medications. These drugs are made available through hospital pharmacies, retail pharmacies, and other distribution channels for the treatment of conditions such as ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and more.
The DNA repair drugs research report is one of a series of new reports that provides DNA repair drugs market statistics, including the DNA repair drugs industry's global market size, regional shares, competitors with DNA repair drugs market share, detailed DNA repair drugs market segments, market trends and opportunities, and any further data you may need to thrive in the DNA repair drugs industry. This DNA repair drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The DNA repair drugs market consists of sales of veliparib, methyl methane sulfonate, mitomycin C, and cisplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. DNA Repair Drugs Market Characteristics3. DNA Repair Drugs Market Trends and Strategies4. DNA Repair Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global DNA Repair Drugs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the DNA Repair Drugs Market34. Recent Developments in the DNA Repair Drugs Market
5. Global DNA Repair Drugs Growth Analysis and Strategic Analysis Framework
6. DNA Repair Drugs Market Segmentation
7. DNA Repair Drugs Market Regional and Country Analysis
8. Asia-Pacific DNA Repair Drugs Market
9. China DNA Repair Drugs Market
10. India DNA Repair Drugs Market
11. Japan DNA Repair Drugs Market
12. Australia DNA Repair Drugs Market
13. Indonesia DNA Repair Drugs Market
14. South Korea DNA Repair Drugs Market
15. Western Europe DNA Repair Drugs Market
16. UK DNA Repair Drugs Market
17. Germany DNA Repair Drugs Market
18. France DNA Repair Drugs Market
19. Italy DNA Repair Drugs Market
20. Spain DNA Repair Drugs Market
21. Eastern Europe DNA Repair Drugs Market
22. Russia DNA Repair Drugs Market
23. North America DNA Repair Drugs Market
24. USA DNA Repair Drugs Market
25. Canada DNA Repair Drugs Market
26. South America DNA Repair Drugs Market
27. Brazil DNA Repair Drugs Market
28. Middle East DNA Repair Drugs Market
29. Africa DNA Repair Drugs Market
30. DNA Repair Drugs Market Competitive Landscape and Company Profiles
31. DNA Repair Drugs Market Other Major and Innovative Companies
35. DNA Repair Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
DNA Repair Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on dna repair drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dna repair drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dna repair drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Drugs2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
3) By Application: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Breast Cancer; Other Applications
Subsegments:
1) By Olaparib: Tablets; Capsules; Combination Therapies2) By Rucaparib: Tablets; Monotherapy; Combination with Other Cancer Treatments
3) By Niraparib: Capsules; Extended-Release Formulations; Maintenance Therapy Applications
4) By Talazoparib: Capsules; Combination with Immunotherapy; High-Dose and Low-Dose Options
5) By Other Drugs: Experimental PARP Inhibitors; Generic and Biosimilar Versions; Next-Generation DNA Damage Response (DDR) Inhibitors
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Private Limited
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- GlaxoSmithKline plc.
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Amgen Inc.
- Merck KGaA
- Regeneron Pharmaceuticals Inc.
- Biogen Inc.
- Ono Pharmaceutical Co. Ltd.
- Jiangsu HengRui Medicine Co. Ltd.
- BioMarin Pharmaceutical Inc.
- Genentech Inc.
- ClovisOncology Inc.
- Karyopharm Therapeutics Inc.
- Repare Therapeutics Inc.
- Intellia Therapeutics Inc.
- C4 Therapeutics Inc.
- Precision BioSciences
- Artios Pharma Limited
- FoRx Therapeutics AG
- Onxeo SA
- CRISPR Therapeutics AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 13.11 Billion |
| Forecasted Market Value ( USD | $ 27.22 Billion |
| Compound Annual Growth Rate | 20.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
